AU2020349553B2 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) - Google Patents

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Info

Publication number
AU2020349553B2
AU2020349553B2 AU2020349553A AU2020349553A AU2020349553B2 AU 2020349553 B2 AU2020349553 B2 AU 2020349553B2 AU 2020349553 A AU2020349553 A AU 2020349553A AU 2020349553 A AU2020349553 A AU 2020349553A AU 2020349553 B2 AU2020349553 B2 AU 2020349553B2
Authority
AU
Australia
Prior art keywords
formula
theta
degrees
crystalline form
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020349553A
Other languages
English (en)
Other versions
AU2020349553A1 (en
Inventor
Ganfeng Cao
Qun Li
Hongwu YU
Huaping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of AU2020349553A1 publication Critical patent/AU2020349553A1/en
Application granted granted Critical
Publication of AU2020349553B2 publication Critical patent/AU2020349553B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AU2020349553A 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) Active AU2020349553B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902322P 2019-09-18 2019-09-18
US62/902,322 2019-09-18
PCT/US2020/051563 WO2021055797A1 (en) 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Publications (2)

Publication Number Publication Date
AU2020349553A1 AU2020349553A1 (en) 2022-04-07
AU2020349553B2 true AU2020349553B2 (en) 2026-07-02

Family

ID=72717922

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020349553A Active AU2020349553B2 (en) 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Country Status (12)

Country Link
US (2) US12414953B2 (cg-RX-API-DMAC10.html)
EP (1) EP4031555A1 (cg-RX-API-DMAC10.html)
JP (1) JP7706166B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220065811A (cg-RX-API-DMAC10.html)
CN (1) CN114829370B (cg-RX-API-DMAC10.html)
AU (1) AU2020349553B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022004630A2 (cg-RX-API-DMAC10.html)
CA (1) CA3154566A1 (cg-RX-API-DMAC10.html)
IL (1) IL291417B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022003340A (cg-RX-API-DMAC10.html)
WO (1) WO2021055797A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202203680B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2017032840A1 (en) * 2015-08-26 2017-03-02 Janssen Pharmaceutica Nv Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
WO2019032859A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2019178368A1 (en) * 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AU2015301196A1 (en) * 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
WO2017206904A1 (zh) * 2016-06-02 2017-12-07 上海海雁医药科技有限公司 Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2017218802A1 (en) * 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
BR112019006414A2 (pt) * 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
KR101785870B1 (ko) 2016-11-03 2017-10-13 한규락 오르골 장치
EP3700906A1 (en) * 2017-10-26 2020-09-02 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2017032840A1 (en) * 2015-08-26 2017-03-02 Janssen Pharmaceutica Nv Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
WO2019032859A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
WO2019178368A1 (en) * 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Also Published As

Publication number Publication date
JP2022548689A (ja) 2022-11-21
US20230029094A1 (en) 2023-01-26
CN114829370A (zh) 2022-07-29
ZA202203680B (en) 2025-12-17
US20250367205A1 (en) 2025-12-04
US12414953B2 (en) 2025-09-16
CN114829370B (zh) 2025-10-28
IL291417B2 (en) 2025-12-01
KR20220065811A (ko) 2022-05-20
MX2022003340A (es) 2022-06-14
WO2021055797A1 (en) 2021-03-25
CA3154566A1 (en) 2021-03-25
BR112022004630A2 (pt) 2022-05-31
AU2020349553A1 (en) 2022-04-07
WO2021055797A9 (en) 2021-04-22
EP4031555A1 (en) 2022-07-27
IL291417A (en) 2022-05-01
JP7706166B2 (ja) 2025-07-11
IL291417B1 (en) 2025-08-01